The firm has received a new patent (9,757,384) from the relevant US office, related to the use of certain pharmaceutical formulations to reduce one or more aggressive behaviours in a patient with genetics disorders Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).
The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR).
“This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” said Anish Bhatnagar, Soleno Therapeutics' chief executive in a statement today.
"Importantly, this most recent patent will provide protection of associated claims into 2035. We expect to leverage additional intellectual property opportunities for DCCR over the coming months.”
Soleno expects to begin a Phase III clinical trial of DCCR in Prader-Willi syndrome (PWS) by the end of 2017.
It is now finalising the design of a randomized, double-blind placebo-controlled study to treat around 100 patients.
This study is expected to take around nine to 12 months to complete. DCCR has orphan drug status for the treatment of PWS in the USA.